LLY vs NAMS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NAMS exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 1/9, indicating very weak financial health. Despite a 'Strong Buy' analyst consensus and a high current ratio of 7.88, the company has suffered a catastrophic revenue collapse of -99.80% YoY and trades at an unsustainable Price/Sales ratio of 175.97. The stark disconnect between the bullish analyst targets and the bearish insider selling ($46.22M in sales) suggests a high-risk speculative profile. While zero debt provides a temporary safety net, the operational metrics are currently non-viable.
Compare Another Pair
Related Comparisons
LLY vs NAMS: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and NewAmsterdam Pharma Company N.V. (NAMS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.